Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Syr-472
2. Trelagliptin
1. 1029877-94-8
2. Trelagliptin (succinate)
3. Syr-472
4. Zafatek
5. Syr111472 Succinate
6. Syr 111472 Succinate
7. Trelagliptin Succinate [usan]
8. Syr-472 Succinate
9. Syr 472
10. (r)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)methyl)-4-fluorobenzonitrile Succinate
11. Syr-111472 Succinate
12. 2-[[6-[(3r)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile;butanedioic Acid
13. Butanedioic Acid, Compd. With 2-((6-((3r)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl)methyl)-4-fluorobenzonitrile (1:1)
14. 4118932z90
15. Syr472
16. Mfcd22665720
17. Zafatek (tn)
18. Unii-4118932z90
19. Schembl878010
20. Chembl2105754
21. Dtxsid00145602
22. Ex-a378
23. Trelagliptin Succinate [mi]
24. Trelagliptin Succinate (jan/usan)
25. Trelagliptin Succinate [jan]
26. Hy-15408a
27. Akos025402003
28. Ccg-269496
29. Cs-1042
30. Trelagliptin Succinate [who-dd]
31. Ac-28020
32. As-10248
33. S5063
34. D10179
35. F20669
36. Trelagliptin Succinate(syr 111472 Succinate)
37. A852132
38. Q27258374
39. (r)-2-[[6-(3-amino-1-piperidyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1-pyrimidinyl]methyl]-4-fluorobenzonitrile
| Molecular Weight | 475.5 g/mol |
|---|---|
| Molecular Formula | C22H26FN5O6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 6 |
| Exact Mass | 475.18671173 g/mol |
| Monoisotopic Mass | 475.18671173 g/mol |
| Topological Polar Surface Area | 168 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 750 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
ABOUT THIS PAGE
A Trelagliptin Succinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trelagliptin Succinate, including repackagers and relabelers. The FDA regulates Trelagliptin Succinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trelagliptin Succinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Trelagliptin Succinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Trelagliptin Succinate supplier is an individual or a company that provides Trelagliptin Succinate active pharmaceutical ingredient (API) or Trelagliptin Succinate finished formulations upon request. The Trelagliptin Succinate suppliers may include Trelagliptin Succinate API manufacturers, exporters, distributors and traders.
click here to find a list of Trelagliptin Succinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Trelagliptin Succinate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Trelagliptin Succinate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Trelagliptin Succinate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Trelagliptin Succinate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Trelagliptin Succinate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Trelagliptin Succinate suppliers with NDC on PharmaCompass.
Trelagliptin Succinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trelagliptin Succinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trelagliptin Succinate GMP manufacturer or Trelagliptin Succinate GMP API supplier for your needs.
A Trelagliptin Succinate CoA (Certificate of Analysis) is a formal document that attests to Trelagliptin Succinate's compliance with Trelagliptin Succinate specifications and serves as a tool for batch-level quality control.
Trelagliptin Succinate CoA mostly includes findings from lab analyses of a specific batch. For each Trelagliptin Succinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trelagliptin Succinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Trelagliptin Succinate EP), Trelagliptin Succinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trelagliptin Succinate USP).
LOOKING FOR A SUPPLIER?
